Zejing pharmaceutical: an advance loss of 372 million yuan to 455 million yuan in 2021

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

Unpacking China | Key Chinese Firms to Watch This Week （05/07/2026-11/07/2026）

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

Huawei Schedules Global Launch of Pura 90 in Malaysia, Signaling Potential Return of 5G Smartphones to Overseas Markets

Huawei Technologies (华为) has announced that it will hold the international launch event for its new Pura 90 series in Kuala Lumpur, Malaysia, on July 14, marking one of the company’s most closely watched overseas smartphone releases in recent years.

Unpacking China | Key Chinese Firms to Watch This Week （28/06/2026-04/07/2026）

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.